This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity
by Zacks Equity Research
At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.
Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication
by Zacks Equity Research
Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO
by Zacks Equity Research
Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Novartis (NVS) Announces Various Data Presentations at ASCO
by Zacks Equity Research
Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer
by Zacks Equity Research
AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.
Roche Presents Positive Data on Xolair & Updates From ASCO
by Zacks Equity Research
Roche (RHHBY) reports positive data from late-stage studies on allergic asthma drug, Xolair, for a new indication, and additional results on Tecentriq and Avastin combo at ASCO.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer
by Zacks Equity Research
Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO
by Zacks Equity Research
Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.
Bristol-Myers Squibb (BMY) Stock Moves -1.11%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $45.37, marking a -1.11% move from the previous day.
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Novartis (NVS) Reports Positive Phase III Data on Asthma Drug
by Zacks Equity Research
Novartis' (NVS) investigational, once-daily, fixed dose combination asthma candidate, containing indacaterol acetate and mometasone furoate, meets goals.
Bayer's Aliqopa Gets Breakthrough Therapy Status by FDA
by Zacks Equity Research
Bayer's (BAYRY) Aliqopa gets Breakthrough Thearpy designation from the FDA for the treatment of adult patients with relapsed marginal zone lymphoma, who have received at least two prior therapies.
BMY or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. NVO: Which Stock Is the Better Value Option?
Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma
by Zacks Equity Research
Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy
by Zacks Equity Research
Novartis (NVS) obtains FDA approvals for a breast cancer drug and a gene therapy for pediatric patients.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems
by Zacks Equity Research
Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
Why Is Bristol-Myers (BMY) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
by Kinjel Shah
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
5 ROE Stocks to Buy as Trade Concerns Spur Market Volatility
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
Synlogic (SYBX) Enters Cancer Collaboration with Roche
by Zacks Equity Research
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
Novartis Reports Data on Asthma Drug, Update from Annual Meet
by Zacks Equity Research
Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
Array BioPharma Gains on Colorectal Cancer Study Success
by Zacks Equity Research
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS
by Zacks Equity Research
Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.